Last update 25 Oct 2025

[161Tb]Tb PSMA I&Tc

Overview

Basic Info

Drug Type
Peptide Conjugate Radionuclide, Therapeutic radiopharmaceuticals
Synonyms-
Target
PSMA
Action
inhibitors
Mechanism
PSMA inhibitors(Prostate-specific membrane antigen inhibitors)
Therapeutic Areas
NeoplasmsUrogenital Diseases
Active Indication
Metastatic castration-resistant prostate cancer
Inactive Indication-
Originator Organization
Peter MacCallum Cancer InstitutePeter MacCallum Cancer Institute
Active Organization
Peter MacCallum Cancer InstitutePeter MacCallum Cancer Institute
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
login
or
view full example data
Boost your research with our ADC technology data.

Related

2
Clinical Trials associated with [161Tb]Tb PSMA I&Tc
NCT07208240
/ RecruitingPhase 1/2IIT
Tb-PSMA-I&T Radionuclide Neo-Adjuvant Treatment in Patients With Locally Advanced Prostate Cancer Before Radical Prostatectomy: TbeforePROST Trial.
NCT05521412
/ RecruitingPhase 1/2IIT
EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T: Phase I/II Study
100 Clinical Results associated with [161Tb]Tb PSMA I&Tc
Login to view more data
100 Translational Medicine associated with [161Tb]Tb PSMA I&Tc
Login to view more data
100 Patents (Medical) associated with [161Tb]Tb PSMA I&Tc
Login to view more data
100 Deals associated with [161Tb]Tb PSMA I&Tc
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic castration-resistant prostate cancerPhase 2
Australia
Peter MacCallum Cancer InstitutePeter MacCallum Cancer Institute
29 Sep 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT05521412 (VIOLET, ASCO2025)
Phase 1/2
Metastatic castration-resistant prostate cancer
PSMA-positive disease
30
Terbium-161[161Tb]Tb-PSMA-I&T
xqrwptjyae(ydruakakvb) = ohrdljdvfb hqjqtgdhgt (rqlnktnizw, 51 - 85)
View more
Positive
30 May 2025
VIOLET (SNMMI2024)
Phase 1/2
Metastatic castration-resistant prostate cancer
30
jmkienijvf(khzqdyztin) = jiywmtigbv scnjvlfrbh (mswlytxnme, 0.05)
View more
Positive
09 Jun 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free